|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/497 | (2000.01) |
| A61K 39/00 | (1974.07) | ||
| A61P 35/00 | (2000.01) | ||
| A61K 31/496 | (2000.01) | ||
| A61K 39/395 | (1980.01) | ||
| A61K 45/06 | (1974.07) | ||
| A61P 35/02 | (2000.01) | ||
| C07K 16/28 | (1995.01) |
| (11) | Number of the document | 3796912 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19732494.0 |
| Date of filing the European patent application | 2019-05-22 | |
| (97) | Date of publication of the European application | 2021-03-31 |
| (45) | Date of publication and mention of the grant of the patent | 2023-02-15 |
| (46) | Date of publication of the claims translation | 2023-06-12 |
| (86) | Number | PCT/US2019/033505 |
| Date | 2019-05-22 |
| (87) | Number | WO 2019/226761 |
| Date | 2019-11-28 |
| (30) | Number | Date | Country code |
| 201862675639 P | 2018-05-23 | US |
| (72) |
PIERCE, Daniel, W. , US
WONG, Lilly, L. , US
|
| (73) |
Celgene Corporation ,
86 Morris Avenue, Summit, NJ 07901,
US
|
| (74) |
Aušra PAKĖNIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Antiproliferaciniai junginiai ir bispecifinis antikūnas prieš BCMA ir CD3, skirtas kompleksiniam naudojimui |
| ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USE |
| Payment date | Validity (years) | Amount | |
| 2025-04-22 | 7 | 162.00 EUR |
| 2026-05-22 |